Complementary mechanisms in soft-tissue models
BPC-157 and thymosin beta-4 have been studied through distinct mechanisms — FAK-paxillin signalling and growth-factor modulation for BPC-157, and actin-binding, cell-migration and angiogenic activity for thymosin beta-4. Preclinical repair studies of each compound report improved healing endpoints across tendon, muscle and wound models.
In plain English
The two peptides are combined in research because they appear to act on different parts of the repair process. Direct combination trials are scarce; the pairing is a protocol convention, not a proven synergy.